Barbuti, Margherita
Brancati, Giulio E.
Calderone, Alba
Fierabracci, Paola
Salvetti, Guido
Weiss, Francesco
Carignani, Giulia
Santini, Ferruccio
Perugi, Giulio http://orcid.org/0000-0001-5556-1858
Funding for this research was provided by:
Università di Pisa
Article History
Received: 13 March 2021
Accepted: 31 May 2021
First Online: 16 June 2021
Declarations
:
: Prof. Perugi acted as consultant to Lundbeck, Angelini, FB-Health. He received a scholarship/research support from Lundbeck and Angelini. He is a member of the speaker/advisory board of Sanofi-Aventis, Lundbeck, FB-Health, Angelini. Prof. Santini has acted as a consultant, has received grant/research support and/or is on the speaker/advisory board for NovoNordisk, Bruno Farmaceutici, Aegerion-Amrit, Bio Italia srl. Prof Maremmani served as Board Member for Angelini, Camurus, CT Sanremo, D&A Pharma, Gilead, Indivior, Lundbeck, Molteni, MSD, Mundipharma. Other authors have no affiliation or financial interest in any organization that may constitute a conflict of interest.
: The study was carried out in accordance with The Code of Ethics of the World Medical Association (Declaration of Helsinki) and was approved by the Ethics Committee of the University of Pisa.
: Because the study is based on retrieved clinical charts, informed consent is not required for participation in the study.
: Because the study is based on retrieved clinical charts, informed consent is not required for publication.